Tags

Type your tag names separated by a space and hit enter

Blonanserin patch vs. Other Antipsychotics for Acute Schizophrenia: A Systematic Review of Double-blind, Randomized, Placebo-controlled, Phase 3 Trials in Japan.
Pharmacopsychiatry. 2020 Apr; 53(3):122-132.P

Abstract

INTRODUCTION

The use of the blonanserin patch (BLO-P) for schizophrenia treatment was approved in Japan in 2019. This systematic review of trials in Japan assessed the efficacy and safety profile of BLO-P compared with other antipsychotics.

METHODS

The systematic review included 6-week, double-blind, randomized, placebo-controlled, phase 3 trials in Japan that included patients with acute schizophrenia. Pooled data for patients receiving BLO-P 40 and 80 mg/day (BLO-P40+80) were compared with pooled data for patients receiving asenapine 10 and 20 mg/day (ASE10+20) and data for those receiving brexpiprazole 2 mg/day (BRE2) and paliperidone extended-release 6 mg/day (PAL-ER6).

RESULTS

All the investigated treatments were superior to placebo in reducing the Positive and Negative Syndrome Scale (PANSS) total score; the Hedges' g values (95% confidence interval) for BLO-P40+80, ASE10+20, BRE2, and PAL-ER6 were-0.40 (-0.58,-0.22),-0.61 (-0.79,-0.42),-0.33 (-0.60,-0.07), and-0.69 (-0.93,-0.45), respectively. There were differences among the antipsychotics in the incidence of various individual adverse events.

DISCUSSION

BLO-P40+80 may have a good efficacy/safety/tolerability profile for the treatment of patients with acute schizophrenia.

Authors+Show Affiliations

Department of Psychiatry, Fujita Health University, Toyoake, Japan.Department of Psychiatry University of Occupational and Environmental Health Japan, Psychiatry, Kitakyushu, Japan.Department of Psychiatry, Fujita Health University, Toyoake, Japan.Department of Psychiatry, Fujita Health University, Toyoake, Japan.Department of Psychiatry, Fujita Health University, Toyoake, Japan.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32000271

Citation

Kishi, Taro, et al. "Blonanserin Patch Vs. Other Antipsychotics for Acute Schizophrenia: a Systematic Review of Double-blind, Randomized, Placebo-controlled, Phase 3 Trials in Japan." Pharmacopsychiatry, vol. 53, no. 3, 2020, pp. 122-132.
Kishi T, Yoshimura R, Matsuda Y, et al. Blonanserin patch vs. Other Antipsychotics for Acute Schizophrenia: A Systematic Review of Double-blind, Randomized, Placebo-controlled, Phase 3 Trials in Japan. Pharmacopsychiatry. 2020;53(3):122-132.
Kishi, T., Yoshimura, R., Matsuda, Y., Sakuma, K., & Iwata, N. (2020). Blonanserin patch vs. Other Antipsychotics for Acute Schizophrenia: A Systematic Review of Double-blind, Randomized, Placebo-controlled, Phase 3 Trials in Japan. Pharmacopsychiatry, 53(3), 122-132. https://doi.org/10.1055/a-1096-1266
Kishi T, et al. Blonanserin Patch Vs. Other Antipsychotics for Acute Schizophrenia: a Systematic Review of Double-blind, Randomized, Placebo-controlled, Phase 3 Trials in Japan. Pharmacopsychiatry. 2020;53(3):122-132. PubMed PMID: 32000271.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Blonanserin patch vs. Other Antipsychotics for Acute Schizophrenia: A Systematic Review of Double-blind, Randomized, Placebo-controlled, Phase 3 Trials in Japan. AU - Kishi,Taro, AU - Yoshimura,Reiji, AU - Matsuda,Yuki, AU - Sakuma,Kenji, AU - Iwata,Nakao, Y1 - 2020/01/30/ PY - 2020/1/31/pubmed PY - 2020/1/31/medline PY - 2020/1/31/entrez SP - 122 EP - 132 JF - Pharmacopsychiatry JO - Pharmacopsychiatry VL - 53 IS - 3 N2 - INTRODUCTION: The use of the blonanserin patch (BLO-P) for schizophrenia treatment was approved in Japan in 2019. This systematic review of trials in Japan assessed the efficacy and safety profile of BLO-P compared with other antipsychotics. METHODS: The systematic review included 6-week, double-blind, randomized, placebo-controlled, phase 3 trials in Japan that included patients with acute schizophrenia. Pooled data for patients receiving BLO-P 40 and 80 mg/day (BLO-P40+80) were compared with pooled data for patients receiving asenapine 10 and 20 mg/day (ASE10+20) and data for those receiving brexpiprazole 2 mg/day (BRE2) and paliperidone extended-release 6 mg/day (PAL-ER6). RESULTS: All the investigated treatments were superior to placebo in reducing the Positive and Negative Syndrome Scale (PANSS) total score; the Hedges' g values (95% confidence interval) for BLO-P40+80, ASE10+20, BRE2, and PAL-ER6 were-0.40 (-0.58,-0.22),-0.61 (-0.79,-0.42),-0.33 (-0.60,-0.07), and-0.69 (-0.93,-0.45), respectively. There were differences among the antipsychotics in the incidence of various individual adverse events. DISCUSSION: BLO-P40+80 may have a good efficacy/safety/tolerability profile for the treatment of patients with acute schizophrenia. SN - 1439-0795 UR - https://www.unboundmedicine.com/medline/citation/32000271/Blonanserin_patch_vs._Other_Antipsychotics_for_Acute_Schizophrenia:_A_Systematic_Review_of_Double-blind,_Randomized,_Placebo-controlled,_Phase_3_Trials_in_Japan L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/a-1096-1266 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.